RU2018103901A - Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение - Google Patents
Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение Download PDFInfo
- Publication number
- RU2018103901A RU2018103901A RU2018103901A RU2018103901A RU2018103901A RU 2018103901 A RU2018103901 A RU 2018103901A RU 2018103901 A RU2018103901 A RU 2018103901A RU 2018103901 A RU2018103901 A RU 2018103901A RU 2018103901 A RU2018103901 A RU 2018103901A
- Authority
- RU
- Russia
- Prior art keywords
- group
- disease
- compound
- formula
- alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/25—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/24—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/26—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/30—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/32—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Claims (76)
1. Способ лечения пациента, страдающего заболеванием, при котором показано лечение цистеамином, включающий введение пациенту эффективного количества композиции, содержащей соединение формулы I или его дисульфид:
где:
R1 и R2 независимо выбраны из группы, состоящей из H и C1-5-алкила; или
R1 и R2, взятые вместе с атомом углерода, к которому они присоединены, образуют 3-, 4-, 5-, 6-, 7- или 8-членное карбоциклическое кольцо;
R3 и R4 независимо выбраны из группы, состоящей из H и C1-5-алкила; или
R3 и R4, взятые вместе с атомом углерода, к которому они присоединены, образуют 3-, 4-, 5-, 6-, 7- или 8-членное карбоциклическое кольцо;
G выбран из группы, состоящей из -NR5R6 и -CR7R8NR5R6;
R5 и R6 независимо выбраны из группы, состоящей из H и C1-5-алкила; или
R5 и R6, взятые вместе с атомом азота, к которому они присоединены, образуют 3-, 4-, 5-, 6-, 7- или 8-членное гетероциклическое кольцо;
R7 и R8 независимо выбраны из группы, состоящей из H и C1-5-алкила; или
R7 и R8, взятые вместе с атомом углерода, к которому они присоединены, образуют 3-, 4-, 5-, 6-, 7- или 8-членное карбоциклическое кольцо;
R2 и R6, взятые вместе с атомами, к которым они присоединены, образуют 4-, 5-, 6-, 7-, 8-, 9- или 10-членное гетероциклическое кольцо;
R4 и R6, взятые вместе с атомами, к которым они присоединены, образуют 4-, 5-, 6-, 7-, 8-, 9- или 10-членное гетероциклическое кольцо;
R2 и R8, взятые вместе с атомами, к которым они присоединены, образуют 3-, 4-, 5-, 6-, 7- или 8-членное карбоциклическое кольцо; или
R2 и R4, взятые вместе с атомами, к которым они присоединены, образуют 3-, 4-, 5-, 6-, 7- или 8-членное карбоциклическое кольцо;
при условии, что когда G представляет собой -NH2, по крайней мере, один из R1, R2, R3 и R4 является иным, чем H.
2. Способ по п.1, отличающийся тем, что R5 и R6 независимо выбраны из группы, состоящей из H, метила и этила.
3. Способ по п.1, отличающийся тем, что R5 и R6, взятые вместе с атомом азота, к которому они присоединены, образуют 5-членное гетероциклическое кольцо.
4. Способ по любому из предшествующих пунктов, отличающийся тем, что R4 представляет собой метил.
5. Способ по п.4, отличающийся тем, что R3 представляет собой метил.
6. Способ по любому из пп.1-3, отличающийся тем, что R3 и R4, взятые вместе с атомом углерода, к которому они присоединены, образуют 3-членное карбоциклическое кольцо.
7. Способ по любому из предшествующих пунктов, отличающийся тем, что R2 представляет собой метил.
8. Способ по п.7, отличающийся тем, что R1 представляет собой метил.
9. Способ по любому из пп.1-6, отличающийся тем, что R1 и R2, взятые вместе с атомом углерода, к которому они присоединены, образуют 3-членное карбоциклическое кольцо.
10. Способ по п.1, отличающийся тем, что G представляет собой -CR7R8NR5R6, и R2 и R6, взятые вместе с атомами, к которым они присоединены, образуют 6-членное гетероциклическое кольцо.
11. Способ по п.10, отличающийся тем, что R5 представляет собой метил.
12. Способ по п.1, отличающийся тем, что G представляет собой -NR5R6, и R2 и R6, взятые вместе с атомами, к которым они присоединены, образуют 4- или 6-членное гетероциклическое кольцо.
13. Способ по п.12, отличающийся тем, что R5 представляет собой H.
14. Способ по любому из предшествующих пунктов, отличающийся тем, что R7 и R8 оба представляют собой H.
15. Способ по п.1, отличающийся тем, что соединение формулы I выбрано из группы, состоящей из:
и их дисульфидов.
16. Способ по п.1, отличающийся тем, что соединение формулы I выбрано из группы, состоящей из:
17. Способ по п.16, отличающийся тем, что R1, R2, R3, R4, R5, R6, R7 и R8 независимо выбраны из группы, состоящей из H и C1-5-алкила.
18. Способ по п.16, отличающийся тем, что R1, R2, R3, R4, R5, R6, R7 и R8 независимо выбраны из группы, состоящей из H и метила.
19. Способ лечения пациента, страдающего заболеванием, при котором показано лечение цистеамином, включающий введение пациенту эффективного количества композиции, содержащей соединение формулы II, формулы III или его дисульфид:
где:
L представляет собой углеводородную связывающую группу;
R9 и R10 независимо выбраны из группы, состоящей из H, C1-5алкила и CO(C1-5алкил); или
R9 и R10, взятые вместе с атомом азота, к которому они присоединены, образуют 3-, 4-, 5-, 6-, 7- или 8-членное гетероциклическое кольцо;
A представляет собой гетероциклическое кольцо, содержащее один атом N; и
n равно 0, 1, 2 или 3;
где атом S в соединении формулы II или формулы III находится на расстоянии от около 3,6 до около 4,7 ангстрем от атома N в соединении;
при условии, что соединение формулы II не представляет собой цистеамин.
20. Способ по п.19, отличающийся тем, что L представляет собой 3-, 4-, 5-, 6-, 7- или 8-членное циклоалкильное кольцо или 6-членное арильное кольцо.
21. Способ по п.19, отличающийся тем, что L представляет собой C1-5алкил.
22. Способ по любому из пп.19-21, отличающийся тем, что L замещен одной-четырьмя группами, выбранными из галогена, C1-5алкила, C3-5циклоалкила и -СO2(C1-5алкил).
23. Способ по п.19, отличающийся тем, что A представляет собой 3-, 4-, 5-, 6-, 7- или 8-членное моноциклическое гетероциклоалкильное кольцо, 6-, 7- или 8-членное бициклическое гетероциклоалкильное кольцо или 5- или 6-членное гетероарильное кольцо.
24. Способ по п.19, отличающийся тем, что соединение формулы III имеет структуру IIIa:
где R11 выбран из группы, состоящей из H и C1-5алкила.
25. Способ по любому из пп.19, 23 или 24, отличающийся тем, что A замещен одной-четырьмя группами, выбранными из галогена, C1-5алкила, C3-5циклоалкила и -СO2(C1-5алкил).
26. Способ по п.19, отличающийся тем, что атом S в соединении формулы II или формулы III находится на расстоянии от около 3,8 ангстрем до около 4,4 ангстрем от атома N в соединении.
27. Способ по п.26, отличающийся тем, что атом S в соединении формулы II или формулы III находится на расстоянии от около 4,0 ангстрем до около 4,2 ангстрем от атома N в соединении.
28. Способ по п.27, отличающийся тем, что атом S в соединении формулы II или формулы III находится на расстоянии около 4,1 ангстрем от атома N в соединении.
29. Способ по любому из пп.19-28, отличающийся тем, что соединение формулы II, формулы III или его дисульфид снижает уровень цистина у субъекта в количестве, которое составляет, по меньшей мере, 70% от уровня снижения цистина цистеамином.
30. Способ по любому из пп.1-29, отличающийся тем, что соединение формулы I, формула II, формула III или его дисульфид резистентны к метаболизму цистеаминдиоксигеназой (ADO).
31. Способ по п.30, отличающийся тем, что менее 20% соединения формулы I, формулы II, формулы III или его дисульфида метаболизируется цистеаминдиоксигеназой (ADO) при анализе истощения кислорода с использованием чувствительного к кислороду флуоресцентного зонда.
32. Способ по любому из пп.1-31, отличающийся тем, что заболевание выбрано из группы, состоящей из цистиноза, жирового заболевания печени, фиброза, тромботического заболевания, расстройства, связанного с MECP-2, наследственного митохондриального заболевания, неврологического заболевания или расстройства, воспаления и злокачественной опухоли.
33. Способ по п.32, отличающийся тем, что жировая болезнь печени выбрана из группы, состоящей из неалкогольной жировой болезни печени (NAFLD), неалкогольного стеатогепатита (NASH), жировой болезни печени, обусловленной гепатитом, жировой болезни печени, обусловленной ожирением, жировой болезни печени, обусловленной диабетом, жировой болезни печени, обусловленной резистентностью к инсулину, жировой болезни печени, обусловленной гипертриглицеридемией, абеталипопротеинемией, гликогенозом, болезнью Вебера-Крисчена, болезнью Вольмана, острым стеатозом при беременности и липодистрофией.
34. Способ по п.32, отличающийся тем, что фиброз выбран из группы, состоящей из атеросклероза, астмы, фиброза миокарда, фиброза трансплантата органов, коллоидного и гипертрофического рубца, мышечного фиброза, фиброза поджелудочной железы, фиброза костного мозга, интерстициального фиброза печени, цирроза печени и желчного пузыря, склеродермии, фиброза легких, диффузного паренхиматозного заболевания легких, идиопатического интерстициального фиброза, интерстициальной пневмонии, десквамативной интерстициальной пневмонии, респираторного бронхиолита, интерстициальной болезни легких, острой интерстициальной пневмонии, неспецифической интерстициальной пневмонии, криптогенной организующейся пневмонии, лимфоцитарной интерстициальной пневмонии, почечного фиброза и хронического заболевания почек, кистозного фиброза и болезни Альпорта.
35. Способ по п.32, отличающийся тем, что тромботическое заболевание выбрано из группы, состоящей из серповидноклеточной анемии, тромбоза глубоких вен, эмболии легочной артерии, кардиоэмболии, гиперкоагуляционного состояния, тромбофилии, фактора V Ляйдена, дефицита антитромбина III, дефицита белка С, дефицита белка S, мутации гена протромбина (G20210A), гиперхомикстеинемии, синдрома антифосфолипидных антител (APS), тромбоза в результате повышения уровня антител к кардиолипину (ACLA) или синдрома волчаночного антикоагулянта (LA).
36. Способ по п.32, отличающийся тем, что неврологическое заболевание или расстройство выбрано из группы, состоящей из болезни Хантингтона, болезни Паркинсона, бокового амиотрофического склероза, рассеянного склероза, болезни Альцгеймера, спинальной мышечной атрофии, сотрясения мозга, инсульта и травматического повреждения мозга (CTE).
37. Способ по п.32, отличающийся тем, что заболевание, связанное с MECP-2, выбрано из группы, состоящей из синдрома Ретта, аутизма, общего расстройства психологического развития, несиндромальной задержки умственного развития, идиопатической неонатальной энцефалопатии и идиопатической формы церебрального паралича.
38. Способ по п.32, отличающийся тем, что наследственное митохондриальное заболевание выбрано из группы, состоящей из атаксии Фридрейха, наследственной оптической невропатии Лебера (LHON), миоклонической эпилепсии и разорванных красных волокн, митохондриальной энцефаломиопатии, лактацидоза и инсультподобных эпизодов (MELAS), синдрома Кернса-Сейра и подострой некротической энцефаломиопатии (синдром Лея).
39. Способ по п.32, отличающийся тем, что злокачественная опухоль выбрана из группы, состоящей из злокачественной опухоли молочной железы, меланомы, злокачественной опухоли предстательной железы, злокачественной опухоли поджелудочной железы, злокачественной опухоли головы и шеи, злокачественной опухоли легких, немелкоклеточной карциномы легких, злокачественной опухоли почки, злокачественной опухоли толстой и прямой кишки, злокачественной опухоли толстой кишки, злокачественной опухоли яичников, злокачественной опухоли печени и злокачественной опухоли желудка.
40. Соединение, имеющее следующую структуру, или его дисульфид:
где R1 представляет собой C1-5алкил; и
R3, R4, R5, R7 и R8 независимо выбраны из группы, состоящей из H и C1-5-алкила.
41. Соединение, имеющее следующую структуру, или его дисульфид:
где R1, R3, R4, R5, R6 и R7 независимо выбраны из группы, состоящей из H и C1-5-алкила.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562187939P | 2015-07-02 | 2015-07-02 | |
US62/187,939 | 2015-07-02 | ||
US201562387337P | 2015-12-23 | 2015-12-23 | |
US62/387,337 | 2015-12-23 | ||
PCT/US2016/040637 WO2017004485A1 (en) | 2015-07-02 | 2016-07-01 | Ado-resistant cysteamine analogs and uses thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2022103033A Division RU2022103033A (ru) | 2015-07-02 | 2016-07-01 | Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2018103901A true RU2018103901A (ru) | 2019-08-05 |
RU2018103901A3 RU2018103901A3 (ru) | 2020-05-25 |
RU2766579C2 RU2766579C2 (ru) | 2022-03-15 |
Family
ID=56511899
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018103901A RU2766579C2 (ru) | 2015-07-02 | 2016-07-01 | Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение |
RU2022103033A RU2022103033A (ru) | 2015-07-02 | 2016-07-01 | Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2022103033A RU2022103033A (ru) | 2015-07-02 | 2016-07-01 | Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение |
Country Status (14)
Country | Link |
---|---|
US (2) | US10906904B2 (ru) |
EP (1) | EP3316877B1 (ru) |
JP (2) | JP2018525350A (ru) |
KR (1) | KR20180034466A (ru) |
CN (1) | CN108289867A (ru) |
AU (2) | AU2016288230A1 (ru) |
BR (1) | BR112017028448A2 (ru) |
CA (1) | CA2991099A1 (ru) |
ES (1) | ES2770113T3 (ru) |
IL (1) | IL256553B (ru) |
MX (2) | MX2018000202A (ru) |
RU (2) | RU2766579C2 (ru) |
TW (2) | TW202247838A (ru) |
WO (1) | WO2017004485A1 (ru) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3316877B1 (en) | 2015-07-02 | 2019-10-30 | Horizon Orphan LLC | Ado-resistant cysteamine analogs and uses thereof |
EP3615013A1 (en) * | 2017-04-24 | 2020-03-04 | Mercaptor Discoveries, Inc. | Use of thiol compounds to treat neurological disease |
CA3092596A1 (en) * | 2018-03-01 | 2019-09-06 | Suzhou Ng Biomedicine Co., Ltd. | Novel aminothiol reduction of ischemia-reperfusion-induced cell death |
WO2019210035A1 (en) * | 2018-04-25 | 2019-10-31 | Horizon Orphan Llc | Methods of treating excitotoxicity disorders |
Family Cites Families (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2834785A (en) | 1954-11-16 | 1958-05-13 | Lakeside Lab Inc | N-substituted-3-thiol piperidines and thioesters thereof |
GB780027A (en) | 1955-01-20 | 1957-07-31 | Schering Corp | 3-piperidyl ethers and thioethers |
US2809918A (en) | 1955-10-17 | 1957-10-15 | Victor M Hermelin | Sustained release pharmaceutical preparations |
DE2010416B2 (de) | 1970-03-05 | 1979-03-29 | Hoechst Ag, 6000 Frankfurt | Oral anwendbare Arzneiform mit Retardwirkung |
FR2471186A1 (fr) | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
US4301146A (en) | 1980-07-29 | 1981-11-17 | G. D. Searle & Co. | Stabilization of 16-oxygenated prostanoic acid derivatives |
FR2549064B1 (fr) | 1983-07-13 | 1985-10-25 | Rhone Poulenc Sante | Nouveaux derives de synergistines utiles pour la preparation de nouveaux medicaments antimicrobiens et leur preparation |
PH23995A (en) | 1984-01-09 | 1990-02-09 | Janssen Pharmaceutica Nv | 4((bicycle heterocyclyl)-methyl and hetero)piperidines |
DE3586746D1 (de) | 1984-04-03 | 1992-11-19 | Takeda Chemical Industries Ltd | Lipidderivate, ihre produktion und verwendung. |
PH22302A (en) | 1985-02-11 | 1988-07-22 | Fujisawa Pharmaceutical Co | Piperidine compounds |
US4728512A (en) | 1985-05-06 | 1988-03-01 | American Home Products Corporation | Formulations providing three distinct releases |
US4794001A (en) | 1986-03-04 | 1988-12-27 | American Home Products Corporation | Formulations providing three distinct releases |
US5151424A (en) | 1987-07-01 | 1992-09-29 | Janssen Pharmaceutica N.V. | Pharmacologically active (Bicyclic heterocyclyl)methyl and -hetero) substituted hexahydro-1H-azepines and pyrrolidines |
US5071846A (en) | 1987-07-01 | 1991-12-10 | Janssen Pharmaceutica N.V. | Anti-hystaminic [(bicyclic heterocyclyl) methyl and --hetero] substituted hexahydro-1H-azepines and pyrrolidines |
US4988689A (en) | 1987-07-01 | 1991-01-29 | Janssen Pharmaceutica N.V. | ((Pharmacologically active bicyclic heterocyclic)methyl and -heteroatom) substituted hexahydro-1H-azepines and pyrrolidines |
GB2206879A (en) | 1987-07-07 | 1989-01-18 | May & Baker Ltd | Novel pristinamycin IIB derivatives, their preparation and pharmaceutical compositions containing them |
DE3808678A1 (de) | 1988-03-11 | 1989-09-21 | Schering Ag | Anellierte imino-azole, verfahren zu ihrer herstellung und ihre verwendung als mittel mit herbizider wirkung |
EP0339406A1 (en) | 1988-04-19 | 1989-11-02 | Hokuriku Pharmaceutical Co.,Ltd | Quinoline-3-carboxylic acid derivatives, process for preparing the same, and composition exhibiting excellent antibacterial effect containing the same |
FR2635524B1 (fr) | 1988-08-19 | 1992-04-24 | Adir | Nouveaux derives de benzopyrrolidinone, leur procede de preparation et les compositions pharmaceutiques les renfermant |
US5272150A (en) | 1989-04-07 | 1993-12-21 | Janssen Pharmaceutica N.V. | Hydroxyalkylfuranyl derivatives |
CA2015949A1 (en) | 1989-05-22 | 1990-11-22 | Yasuo Ito | Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same |
JPH03118319A (ja) * | 1989-09-30 | 1991-05-20 | Green Cross Corp:The | 抗炎症剤、胃液分泌抑制剤または活性酸素産生抑制剤 |
FR2655649B1 (fr) | 1989-12-12 | 1994-07-08 | Adir | Nouveaux derives de la piperidine, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
US5217980A (en) | 1990-07-19 | 1993-06-08 | Janssen Pharmaceutica N.V. | Oxazolyl and piperidinyl substituted benimidazolyl compounds |
CA2049802A1 (en) | 1990-08-26 | 1992-02-27 | Sadao Oida | Anti-fungal triazole derivatives, their preparation and uses |
KR950005301B1 (ko) | 1990-09-04 | 1995-05-23 | 주식회사대웅제약 | 신규한 퀴놀론 카르복실산 유도체 |
JPH04334357A (ja) | 1991-05-02 | 1992-11-20 | Fujirebio Inc | 酵素阻害作用を有するアシル誘導体 |
US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
MX9205549A (es) * | 1991-09-30 | 1993-05-01 | Jess G Thoene | Metodo para el tratamiento de vih. |
US5554655A (en) * | 1991-09-30 | 1996-09-10 | Jess G. Thoene | Method of treating HIV infection |
EP0623615B1 (de) | 1993-05-01 | 1999-06-30 | MERCK PATENT GmbH | Substituierte 1-Phenyl-oxazolidin-2-on Derivate, deren Herstellung und deren Verwendung als Adhäsionsrezeptor-Antagonisten |
FR2705346B1 (fr) | 1993-05-18 | 1995-08-11 | Union Pharma Scient Appl | Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques . |
US5783703A (en) | 1993-07-01 | 1998-07-21 | Lederle (Japan), Ltd. | Sulfur-containing compounds method for their use and prodction |
EP0804434A1 (en) | 1994-08-02 | 1997-11-05 | MERCK SHARP & DOHME LTD. | Azetidine, pyrrolidine and piperidine derivatives |
US5672709A (en) | 1994-10-24 | 1997-09-30 | Eli Lilly And Company | Heterocyclic compounds and their preparation and use |
ATE201410T1 (de) | 1994-12-12 | 2001-06-15 | Wyeth Lederle Japan Ltd | Verfahren zur herstellung von 1-(4,5-dihydro)2- thiazolyl-3-azetidinthiolderivaten |
JP3724854B2 (ja) | 1995-09-11 | 2005-12-07 | ワイス株式会社 | 1−アザビシクロ[1.1.0]ブタンの製造法 |
GB9523243D0 (en) | 1995-11-14 | 1996-01-17 | Merck Sharp & Dohme | Therapeutic agents |
JP3209679B2 (ja) | 1996-04-05 | 2001-09-17 | 日本ワイスレダリー株式会社 | ジスルフィド化合物およびその製造法 |
GB9610979D0 (en) | 1996-05-24 | 1996-07-31 | Merck Sharp & Dohme | Therapeutic agents |
JPH1143792A (ja) | 1997-07-23 | 1999-02-16 | Asahi Kagaku Kogyo Co Ltd | 酸洗促進剤、酸洗促進剤を含んだ酸洗液組成物およびこれを用いる酸洗方法 |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
AU2114199A (en) | 1998-01-13 | 1999-08-02 | Trustees Of The University Of Pennsylvania, The | Novel dopamine re-uptake inhibitors and methods of synthesizing and using the same |
EP1087937A1 (en) | 1998-06-17 | 2001-04-04 | Du Pont Pharmaceuticals Company | Cyclic hydroxamic acids as metalloproteinase inhibitors |
AU5450199A (en) | 1998-09-10 | 2000-04-03 | Wyeth Lederle Japan, Ltd. | Carbapenem compounds |
AU6508899A (en) * | 1998-10-13 | 2000-05-01 | Du Pont Pharmaceuticals Company | Selective eradication of virally-infected cells by combined use of a cytotoxic agent and an antiviral agent |
WO2000025776A1 (en) * | 1998-10-30 | 2000-05-11 | Nitromed, Inc. | Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use |
BR9806353A (pt) * | 1998-11-10 | 2000-06-20 | Univ Minas Gerais | Processo para a preparação e aplicação farmacológica de novos beta-aminotióis e respectivos sais |
JP2001131067A (ja) * | 1999-08-26 | 2001-05-15 | Sankyo Co Ltd | 血小板凝集抑制剤又は動脈硬化進展抑制剤 |
US6455573B1 (en) | 2000-01-07 | 2002-09-24 | Simon Fraser University | Glycosidase inhibitors and methods of synthesizing same |
US6369243B1 (en) | 2000-01-18 | 2002-04-09 | The Regents Of The Univerisity Of California | Chemical transformation of substrates using nonmetallic, organic catalyst compositions |
GB0013060D0 (en) | 2000-05-31 | 2000-07-19 | Astrazeneca Ab | Chemical compounds |
AU7847901A (en) | 2000-07-19 | 2002-02-05 | Hoffmann La Roche | Pyrrolidine derivatives as metalloprotease inhibitors |
WO2003007875A2 (en) | 2001-07-16 | 2003-01-30 | Hoegestaett Edward | Compounds with analgesic, antipyretic and/or anti-inflammatory activity |
JP2003183280A (ja) | 2001-12-21 | 2003-07-03 | Wyeth Lederle Japan Ltd | カルバペネム化合物 |
JP2003183281A (ja) | 2001-12-21 | 2003-07-03 | Wyeth Lederle Japan Ltd | カルバペネム化合物 |
US7408067B2 (en) | 2002-01-17 | 2008-08-05 | Merck + Co., Inc. | Aza-cyclic compounds as modulators of acetylcholine receptors |
US6743864B2 (en) | 2002-03-12 | 2004-06-01 | Basell Poliolefine Italia S.P.A. | Polyolefin compositions having high tenacity |
US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
SE0300812D0 (sv) | 2003-03-24 | 2003-03-24 | Karolinska Innovations Ab | Use of chemical compounds for preparing pharmaceutical compositions, and method of testing substances for medical effect |
JP2006523692A (ja) | 2003-04-18 | 2006-10-19 | イーライ リリー アンド カンパニー | 5−ht1f作用薬としての(ピペリジニルオキシ)フェニル、(ピペリジニルオキシ)ピリジニル、(ピペリジニルスルファニル)フェニル、および(ピペリジニルスルファニル)ピリジニル化合物 |
WO2005014524A2 (en) * | 2003-08-07 | 2005-02-17 | Wisconsin Alumni Research Foundation | Amino thiol compounds and compositions for use in conjunction with cancer therapy |
JP5460947B2 (ja) | 2003-09-03 | 2014-04-02 | グラクソ グループ リミテッド | 新規調製方法、塩、組成物及び使用 |
DE10348044A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Duale Alanyl-Aminopeptidase- und Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
WO2005039548A2 (en) * | 2003-10-15 | 2005-05-06 | Probiodrug Ag | Use of effectors of glutaminyl and glutamate cyclases |
EP1541143A1 (en) | 2003-12-09 | 2005-06-15 | Graffinity Pharmaceuticals Aktiengesellschaft | Dpp-iv inhibitors |
CN101897970A (zh) | 2003-12-19 | 2010-12-01 | 奥加生物药业(I.P.3)有限公司 | 用于治疗糖尿病的组合物和方法 |
BRPI0510613A (pt) | 2004-05-03 | 2007-10-30 | Omega Bio Pharma Ip3 Ltd | cisteaminas para tratar complicações de hipercolesterolemia e diabete |
JP2006001841A (ja) | 2004-06-15 | 2006-01-05 | Sumitomo Chemical Co Ltd | 含窒素へテロ環化合物の製造方法 |
PL1637141T3 (pl) | 2004-09-21 | 2012-04-30 | Trobio Ab | Stabilizowana kompozycja proteazy zawierająca proteazę serynową, pochodne morfoliny i odwracalne inhibitory tej proteazy serynowej |
MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
SG158860A1 (en) | 2005-01-13 | 2010-02-26 | Wyeth Corp | Processes for the preparation of aminoethoxybenzyl alcohols |
CN101360723A (zh) | 2005-09-16 | 2009-02-04 | 武田药品工业株式会社 | 制备嘧啶二酮衍生物的方法 |
CN101196230A (zh) | 2006-01-06 | 2008-06-11 | 赵文利 | 机械动力多司调制技术 |
HUE049307T2 (hu) | 2006-01-27 | 2020-09-28 | Univ California | Bélben oldódó bevonattal ellátott ciszteamin-bitartrát és cisztamin |
TWI389917B (zh) | 2006-04-13 | 2013-03-21 | Sigma Tau Ind Farmaceuti | 作為心血管疾病治療藥物的雄甾烷與雄甾烯之氮雜環烷基衍生物 |
GB0614947D0 (en) | 2006-07-27 | 2006-09-06 | Isis Innovation | Epitope reduction therapy |
EA200901378A1 (ru) * | 2007-04-19 | 2010-04-30 | Юсб Фарма С.А. | Лиганды гистаминового рецептора н, содержащие циклобутоксигруппу |
US20090163705A1 (en) | 2007-05-21 | 2009-06-25 | Alnylam Pharmaceuticals, Inc. | Cationic lipids |
GB0712494D0 (en) | 2007-06-27 | 2007-08-08 | Isis Innovation | Substrate reduction therapy |
DE102008032561A1 (de) | 2007-07-16 | 2009-01-22 | Basf Se | Verfahren und Mischung zur Reinigung von Alkinen |
US8026285B2 (en) | 2007-09-04 | 2011-09-27 | Bezwada Biomedical, Llc | Control release of biologically active compounds from multi-armed oligomers |
ES2417179T3 (es) * | 2007-11-30 | 2013-08-06 | The Regents Of The University Of California | Métodos para tratar la esteatohepatitis no alcohólica (EHNA) mediante productos basados en cisteamina |
JP2011518127A (ja) | 2008-03-31 | 2011-06-23 | エヴォテック・アクチエンゲゼルシャフト | ヒスタミンh3受容体アンタゴニストとしてのテトラヒドロナフチリジンおよびそれらのアザ誘導体 |
US20110195929A1 (en) | 2008-08-05 | 2011-08-11 | Summit Corporation Plc | Compounds for the treatment of flaviviral infections |
US20110237538A1 (en) | 2008-08-06 | 2011-09-29 | Summit Corporation Plc | Treatment of lysosomal storage disorders and other proteostatic diseases |
WO2010026113A1 (en) | 2008-09-03 | 2010-03-11 | Evotec Neurosciences Gmbh | Acyl- and sufonyl tetrahydronaphthyridines and aza derivatives thereof as histamine h3 receptor antagonists |
WO2010029313A1 (en) | 2008-09-11 | 2010-03-18 | Summit Corporation Plc. | Antiinfective compounds |
TW201011009A (en) | 2008-09-15 | 2010-03-16 | Priaxon Ag | Novel pyrrolidin-2-ones |
WO2010041964A1 (en) | 2008-10-09 | 2010-04-15 | Victoria Link Limited | Methods for the preparation of alkenylamines, cyclic carbamates or dithiocarbamates, and aminoalcohols or aminothiols |
WO2010049678A2 (en) | 2008-10-31 | 2010-05-06 | Summit Corporation Plc | Treatment of energy utilization diseases |
AR074231A1 (es) | 2008-11-27 | 2010-12-29 | Boehringer Ingelheim Int | Derivados de 6, 7, 8, 9-tetrahidro-5h-1, 4, 7, 10a-tetraaza-ciclohept[f]indeno, composiciones farmacéuticas que contienen estos compuestos, su uso en el agonismo del receptor 5-ht2c y procesos para prepararlos. |
KR20120034098A (ko) | 2009-07-11 | 2012-04-09 | 바이엘 파마 악티엔게젤샤프트 | 시클로알킬 기를 사용하는 방사성 표지 방법 |
KR20130010456A (ko) | 2009-11-18 | 2013-01-28 | 에프에이비 파마 에스에이에스 | 신규의 헤테로사이클릭 아크릴아미드 및 약제로서 이의 용도 |
AR079980A1 (es) | 2010-01-13 | 2012-03-07 | Sanofi Aventis | Derivados de oxazolopirimidina sustituida en 2,5,7 |
US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
EA201390616A1 (ru) * | 2010-10-25 | 2013-09-30 | Юниверсите Д'Экс-Марсель | ЛЕЧЕНИЕ НАРУШЕНИЙ, АССОЦИИРОВАННЫХ С ГЕНОМ MeCP2 |
US20120309785A1 (en) * | 2010-12-03 | 2012-12-06 | Bill Piu Chan | Use of Cysteamine in Treating Parkinson's Disease |
CA2732440C (en) * | 2011-02-23 | 2017-10-31 | Universite Laval | Cystamine analogues for the treatment of parkinson`s disease |
WO2013024376A1 (en) | 2011-08-16 | 2013-02-21 | Mahesh Kandula | Compositions and methods for the treatment of atherothrombosis |
MX2014004994A (es) * | 2011-10-26 | 2014-08-27 | Seattle Children S Res Inst | Cisteamina en el tratamiento de enfermedad fibrotica. |
US20140322315A1 (en) * | 2011-11-22 | 2014-10-30 | The Regents Of The University Of California | Cysteamine and/or cystamine for treating ischemic injury |
EP2601940A1 (en) * | 2011-12-05 | 2013-06-12 | Lacer, S.A. | (4-mercapto-piperidin-4-yl)-aminoacetic acid derivatives, pharmaceutical compositions and uses thereof |
MX2016005858A (es) * | 2013-11-06 | 2016-08-11 | Raptor Pharmaceuticals Inc | Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales. |
WO2015150472A2 (en) | 2014-04-01 | 2015-10-08 | Université Libre de Bruxelles | New strategies for treating melanoma |
BR112016026291A2 (pt) | 2014-05-19 | 2017-08-15 | Rempex Pharmaceuticals Inc | Derivados do ácido borônico e usos terapêuticos dos mesmos |
GB201416727D0 (en) * | 2014-09-22 | 2014-11-05 | Novabiotics Ltd | Use |
EP3316877B1 (en) | 2015-07-02 | 2019-10-30 | Horizon Orphan LLC | Ado-resistant cysteamine analogs and uses thereof |
-
2016
- 2016-07-01 EP EP16742095.9A patent/EP3316877B1/en active Active
- 2016-07-01 BR BR112017028448-0A patent/BR112017028448A2/pt not_active Application Discontinuation
- 2016-07-01 RU RU2018103901A patent/RU2766579C2/ru active
- 2016-07-01 AU AU2016288230A patent/AU2016288230A1/en not_active Abandoned
- 2016-07-01 KR KR1020187003329A patent/KR20180034466A/ko unknown
- 2016-07-01 JP JP2017568439A patent/JP2018525350A/ja active Pending
- 2016-07-01 CA CA2991099A patent/CA2991099A1/en not_active Abandoned
- 2016-07-01 TW TW111107368A patent/TW202247838A/zh unknown
- 2016-07-01 CN CN201680050706.6A patent/CN108289867A/zh active Pending
- 2016-07-01 TW TW105121024A patent/TWI759267B/zh not_active IP Right Cessation
- 2016-07-01 WO PCT/US2016/040637 patent/WO2017004485A1/en active Application Filing
- 2016-07-01 MX MX2018000202A patent/MX2018000202A/es unknown
- 2016-07-01 RU RU2022103033A patent/RU2022103033A/ru unknown
- 2016-07-01 ES ES16742095T patent/ES2770113T3/es active Active
- 2016-07-05 US US15/201,969 patent/US10906904B2/en active Active
-
2017
- 2017-12-25 IL IL256553A patent/IL256553B/en active IP Right Grant
-
2018
- 2018-01-08 MX MX2021008819A patent/MX2021008819A/es unknown
-
2021
- 2021-01-19 AU AU2021200321A patent/AU2021200321A1/en not_active Abandoned
- 2021-02-01 US US17/164,428 patent/US11505550B2/en active Active
- 2021-07-05 JP JP2021111589A patent/JP2021152087A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112017028448A2 (pt) | 2018-08-28 |
EP3316877A1 (en) | 2018-05-09 |
RU2022103033A (ru) | 2022-04-01 |
ES2770113T3 (es) | 2020-06-30 |
RU2018103901A3 (ru) | 2020-05-25 |
TW201713324A (zh) | 2017-04-16 |
JP2018525350A (ja) | 2018-09-06 |
US20170002004A1 (en) | 2017-01-05 |
JP2021152087A (ja) | 2021-09-30 |
IL256553B (en) | 2021-03-25 |
CA2991099A1 (en) | 2017-01-05 |
WO2017004485A1 (en) | 2017-01-05 |
AU2016288230A1 (en) | 2018-01-25 |
US10906904B2 (en) | 2021-02-02 |
US11505550B2 (en) | 2022-11-22 |
TWI759267B (zh) | 2022-04-01 |
TW202247838A (zh) | 2022-12-16 |
RU2766579C2 (ru) | 2022-03-15 |
CN108289867A (zh) | 2018-07-17 |
IL256553A (en) | 2018-02-28 |
MX2018000202A (es) | 2018-06-27 |
KR20180034466A (ko) | 2018-04-04 |
US20220024920A1 (en) | 2022-01-27 |
MX2021008819A (es) | 2021-08-24 |
EP3316877B1 (en) | 2019-10-30 |
AU2021200321A1 (en) | 2021-03-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2018103901A (ru) | Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение | |
Tu et al. | Fluorine-18-labeled benzamide analogues for imaging the σ2 receptor status of solid tumors with positron emission tomography | |
EP0471811B1 (en) | Allosteric hemoglobin modifiers | |
McConathy et al. | Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents | |
EP0417870B1 (de) | Chelatbildner zur Komplexierung von radioaktiven Isotopen, deren Metallkomplexe sowie ihre Verwendung in Diagnostik und Therapie | |
Tu et al. | Carbon-11 labeled σ2 receptor ligands for imaging breast cancer | |
JP2018525350A5 (ru) | ||
Mamat et al. | Fluorine‐18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidine‐based radiotracer targeting the receptor tyrosine kinase EphB4 | |
Lang et al. | New methods for labeling RGD peptides with bromine-76 | |
Ruan et al. | Novel 99m Tc labelled complexes with 2-nitroimidazole isocyanide: Design, synthesis and evaluation as potential tumor hypoxia imaging agents | |
Camacho et al. | [99mTc (CO) 3]-radiolabeled bevacizumab: in vitro and in vivo evaluation in a melanoma model | |
Ogawa et al. | Development and evaluation of a radiobromine-labeled sigma ligand for tumor imaging | |
KR101168115B1 (ko) | 방사선동위원소 표지 플루오로벤즈아마이드 유사체, 그 합성 및 진단 영상에서의 그 용도 | |
EP3068765B9 (en) | Process for fluorinating compounds | |
Li et al. | Synthesis and in vitro and in vivo evaluation of three radioiodinated nitroimidazole analogues as tumor hypoxia markers | |
JP4796301B2 (ja) | テクネチウム−99m及びレニウムで標識した小型作用剤及び組織、臓器及び腫瘍の画像化方法 | |
Ogawa et al. | Development of a novel radiobromine-labeled sigma-1 receptor imaging probe | |
Effendi et al. | Synthesis and evaluation of radioiodinated 1-{2-[5-(2-methoxyethoxy)-1H-benzo [d] imidazol-1-yl] quinolin-8-yl} piperidin-4-amine derivatives for platelet-derived growth factor receptor β (PDGFRβ) imaging | |
Fuchs et al. | Oxygen breathing affects 3′-deoxy-3′-18F-fluorothymidine uptake in mouse models of arthritis and cancer | |
Li et al. | Synthesis and biological evaluation of novel 4-benzylpiperazine ligands for sigma-1 receptor imaging | |
WO2014118197A1 (en) | Radiolabeled quinazoline derivatives | |
Sekul et al. | Comparative pressor effect of certain unsaturated acid esters of choline | |
Liu et al. | Deuterium‐substituted 2‐(2′‐((dimethylamino) methyl)‐4′‐[18F](fluoropropoxy) phenylthio) benzenamine as a serotonin transporter imaging agent | |
FR2520737A1 (fr) | Nouveaux hydrazides utiles comme agents de durcissement latents des resines epoxydes, compositions de resine epoxyde durcissables les contenant et resines durcies en derivant | |
Yahiro et al. | Effects of hypoxic cell radiosensitizer doranidazole (PR-350) on the radioresponse of murine and human tumor cells in vitro and in vivo |